[1]LAUER GM, WALKER BD.Hepatitis C virus infection[J].N Engl J Med, 2001, 345 (1) :41-52.
|
[2] SHEPPARD P, KINDSVOGEL W, XU W, et al.IL-28, IL-29and their class II cytokine receptor IL-28R[J].Nat Immunol, 2003, 4 (1) :63-68.
|
[3] GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
|
[4] THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.
|
[5] SUPPIAH V, MOLDOVAN M, AHLENSTIEL G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet, 2009, 41 (9) :1100-1104.
|
[6] TANAKA Y, NISHIDA N, SUGIYAMA M, et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet, 2009, 41 (10) :1105-1109.
|
[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology, Chinese Medical Association.Guidelines for prevention and treatment of hepatitis C[J].J Clin Hepatol, 2004, 20 (4) :197-203. (in Chinese) 中华医学会肝病学分会、传染病与寄生虫病学分会.丙型肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.
|
[8]NIE YH, XU CM.HCV genetic heterogeneity and its host genetics[J].J Clin Hepatol, 2013, 29 (10) :797-800. (in Chinese) 聂永红, 许春梅.HCV异质性及其宿主基因多态性[J].临床肝胆病杂志, 2013, 29 (10) :797-800.
|
[9]PAN QC, YU YS, TANG ZH, et al.Serum IL-21 levels in patients with chronic hepatitis C and clinical significance of IL-21[J].Chin J Clin Pharmacol Ther, 2013, 18 (2) :190-194. (in Chinese) 潘庆春, 余永胜, 汤正好, 等.慢性丙型肝炎患者血清IL-21水平检测及临床意义[J].中国临床药理学与治疗学, 2013, 18 (2) :190-194.
|
[10]WANG DS, PAN Y, NIU JQ, et al.IL-28B genetic variation, susceptibility and spontaneous clearance of hepatitis C virus[J].J Clin Hepatol, 2010, 26 (5) :496-499. (in Chinese) 王东生, 潘煜, 牛俊奇, 等.IL-28B基因变异与丙型肝炎的易感性及其自然清除的关系[J].临床肝胆病杂志, 2010, 26 (5) :496-499.
|
[11]RAUCH A, KUTALIK Z, DESCOMBES P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.
|
[12]MI Y, GAO YT, JIAO XL, et al.Association betvoeen an IL-28B gene polymorphism and susceptiblility to hepatitis C virus infection[J].World Chin J Dig, 2013, 21 (2) :182-187. (in Chinese) 米寅, 高英堂, 焦晓磊, 等.IL-28B基因多态性与丙型肝炎易感性的关系[J].世界华人消化杂志, 2013, 21 (2) :182-187.
|
[13]MAURICIO V, RODRIGO AV, KATHERINE G, et al.IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients[J].World J Gastroenterol, 2011, 17 (31) :3636-3639.
|
[14]HONDA M, SAKAI A, YAMASHITA T, et al.Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of I FN therapy for chronic hepatitis C[J].Gastroenterology, 2010, 139 (2) :499-509.
|
[15]DI MARCO VD, BRONTE F, CALVARUSO V, et al.IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection[J].Haematologica, 2012, 97 (5) :679-686.
|